On January 9th, after three months of suspension of trading, Dean Diagnostics disclosed the plan for the increase. The company intends to win the No. 1 with the actual controllers of the company, Chen Haibin, Dean Holdings and Dean employees at the issue price of 38.69 yuan/share. The issuance of assets management plans and other issues issued 26 million shares, the company plans to raise non-public offerings to raise about 1.006 billion yuan of funds, after deducting the issuance costs, all used to supplement the company's working capital. It is worth mentioning that the company will set up an employee stock ownership plan to participate in the release.

The actual controller subscribes for nearly 60%

The plan shows that Dean diagnosed the number of non-public offerings of 26 million shares, issued by the company's actual controller Chen Haibin, Hangzhou Dean Holdings Co., Ltd. (hereinafter referred to as Dean Holdings), Dean employees win a total of 1, CITIC Securities Health Sharing Quality and Equity Collective Asset Management Plan plans to subscribe for 15 million shares, 5 million shares, 3 million shares and 3 million shares, respectively, with subscription amounts of 580 million yuan, 193 million yuan, 116 million yuan and 116 million yuan respectively. All investors subscribed in cash, the issue price was 38.69 yuan / share, and the actual controller Chen Haibin subscribed for 57.69% of the issued shares.

Specifically, as the actual controller of the company, Chen Haibin plans to subscribe for 15 million shares for 580 million yuan. After the completion of this issuance, Chen Haibin's direct and indirect control of the company's shares will increase to 42.05%; Dean Holdings was established in 2014 12 In the month, Chen Haibin is its controlling shareholder. Xu Min, the company's director, holds a 25% stake in Dean Holdings. The Dean Holdings plans to subscribe for 199 million shares. Dean employees win the No.1 and the quality-issued asset management plan respectively. They subscribed for 3 million shares for each of the 116 million yuan.

It is worth mentioning that Dean employees win the No. 1 trustee for the company's Dean employees to win the No. 1 shareholding plan (the company's 2015 employee stock ownership plan). The holders of this employee stock ownership plan are the middle and above management personnel of the company, the core technology (business) personnel of the company, and other employees who have made significant contributions to the board of directors. The amount of participation in the employee subscription shareholding plan was derived from the legal remuneration of the participants, other legal ways to raise funds and the company's controlling shareholder Chen Haibin borrowed a total of 116 million yuan.

Acquired Shengsheng Biological to enter the field of eugenics genetic testing

I mentioned Bo Shengsheng, I believe most people have never heard of it. In the industry, Hangzhou Bosheng Biotechnology Co., Ltd. is a very low-key company specializing in prenatal screening, neonatal disease screening and prenatal diagnosis and other eugenic genetic and technological entities; , experience and experience in screening and diagnosis of metabolic diseases, representing the world's leading PE neonatal disease screening and prenatal screening system, as well as AI cell genetic chromosome graphics workstation, focusing on the field of birth defect intervention in China; More than 200 screening centers within the scope provide product, technical support, personnel training and subject services.

Dean Diagnostics announced on January 9th that in its “2015 Non-public Issuance of A Shares Stock Plan”, the company and natural persons Zhang Min and Luo Wenmin signed the “Equity Transfer and Capital Increase Agreement”, which agreed to Hangzhou Bosheng Biotechnology Co., Ltd. (hereinafter referred to as Bosheng Bio), after the capital increase, the estimated value is 930 million yuan. The company used self-raised funds of 80 million yuan to increase the capital of Bosheng Bio, holding 8.6% of Bosheng Bio. The company also used self-raised funds of 76.26 million yuan. After the acquisition of Zhang Min’s capital increase, 8.2% equity of Bosheng Bio, and 76.26 million yuan acquired the 8.2% equity of Bo Shengsheng held by Luo Wenmin. After the above capital increase and acquisition, Dean Diagnostics will hold a 25% stake in Bo Sheng Bio.

Institutional Interpretation (Shandong Shenguang Financial Research Institute)

1. As an active promoter of the application of eugenics genetic testing in China, Bosheng Bio is the earliest provider of integrated birth defect intervention solutions in China. In the next three years, Bosheng Bio's net profit will maintain an average annual growth rate of at least 30%.

Disposable Sterile Latex Gloves

Latex Exam Gloves,Disposable Exam Gloves,Sterile Examination Gloves,Latex Examination Gloves Price

Henan Anbang Medical Supplies Co., Ltd. , https://www.anbangmedical.com